News

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring…

10 months ago

FOXO TECHNOLOGIES INC. PROVIDES UPDATE ON ITS BEHAVIORAL HEALTH SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC.

MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), provides an update on Myrtle…

10 months ago

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025…

10 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health…

10 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the…

10 months ago

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) --…

10 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) --…

10 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address…

10 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic…

10 months ago

Annual General Meeting 2025 – GN Store Nord A/S

Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the…

10 months ago